SEARCH
YOUR SEARCH FOR Text 22 RESULTS
1 of Total
0002039219-26-000004 | 4 | Incyte
… Investor Relations Inquiries IR@incyte.com … 0002039219-26-000004 | 4 | Incyte …
Read More
2 of Total
0002039219-26-000002 | 4 | Incyte
… Investor Relations Inquiries IR@incyte.com … 0002039219-26-000002 | 4 | Incyte …
Read More
3 of Total
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… on data from several Phase 2 studies (CITADEL-203, -204 and -205) evaluating parsaclisib as a … neoplasms (MLN): Phase 2 (FIGHT‑203) Tumor agnostic: Phase 2 (FIGHT-207) …
Read More
4 of Total
… price of $59.94 per share expiring June 11, 2034, 11,294 vested Stock Options that have an … price of $61.44 per share expiring June 13, 2033, 9,124 vested Stock Options that have an …
Read More
5 of Total
Financials | Incyte
… beneficial ownership of securities View HTML 0002039219-26-000004.pdf 0002039219-26-000004.rtf 0002039219-26-000004.xls …
Read More
6 of Total
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
…     161,183         GAAP net income   158,203     169,548 Non-GAAP net income   229,459   … to have more than 10 high impact launches by 2030; the potential and progress of programs in …
Read More
7 of Total
Headquarters - Pharmaceutical Research & Development | Incyte.com
… Str. 8, 81379 München Germany Tel: +49 89 203010-850 F: +49 89 203010-890 Visit: Incyte Germany Google Maps …
Read More
8 of Total
Incyte Reports 2023 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
…   481,771                   GAAP net income     203,548     161,432     225,251     199,424 …       104,209       100,489   Net income   $ 203,548     $ 161,432     $ 225,251     $ …
Read More
9 of Total
Incyte Reports 2024 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
…         GAAP net (loss) income   (444,601 )     203,548     (275,053 )     225,251 Non-GAAP net …   104,209   Net (loss) income $ (444,601 )   $ 203,548     $ (275,053 )   $ 225,251             …
Read More
10 of Total
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… neoplasms (MLN): Phase 2 (FIGHT‑203) Tumor agnostic: Phase 2 (FIGHT-207) …   parsaclisib (PI3Kδ) r/r FL: Phase 2 (CITADEL‑203) r/r MZL: Phase 2 (CITADEL‑204) r/r MCL: …
Read More